| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 02/26/2004 | US20040038293 Antibodies to human cd154 |
| 02/26/2004 | US20040038292 Comprises nucleotide sequences which code wound healing proteins for treatment and prevention of scarring, fibrosis, restenosis post angioplasty, psoriasis, benign prostatic hyperplasia, glaucoma and nervous suystem disorders |
| 02/26/2004 | US20040038209 Comprises nucleotide sequences coding beta -carotene dioxygenase which cleaves beta carotene and produces vitamin a aldehyde; improving nutritional value of plants, microorganisms and animal feeds |
| 02/26/2004 | US20040037909 Composition comprising the extract of actinidia arguta and related species for the prevention and treatment of allergic disease and non-allergic inflammatory disease |
| 02/26/2004 | US20040037827 Administering antibody to integrin |
| 02/26/2004 | DE10232020A1 Neurorezeptoraktive Heteroarencarboxamide Neuroreceptor Active Heteroarencarboxamide |
| 02/25/2004 | EP1391512A1 Polypeptide serving as angiogenic marker and dna thereof |
| 02/25/2004 | EP1391199A1 Carboxylic acid derivatives and drugs containing the same as the active ingredient |
| 02/25/2004 | EP1390740A1 Methods and formulations for increasing the affinity of a 1? adenosine receptor ligands for the a 1? adenosine receptor |
| 02/25/2004 | EP1390385A2 Nucleic acid based modulation of female reproductive diseases and conditions |
| 02/25/2004 | EP1390366A1 The citrate salt of 5,8,14,-triazatetracyclo(10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaene |
| 02/25/2004 | EP1390349A1 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands |
| 02/25/2004 | EP1390073A2 Compositions having enhanced pharmacokinetic characteristics |
| 02/25/2004 | EP1390054A2 Mu-conopeptides |
| 02/25/2004 | EP1390036A1 Prostanoic acid derivatives as agents for lowering intraocular pressure |
| 02/25/2004 | EP1390035A1 Method for treating ocular hypertension and glaucoma |
| 02/25/2004 | EP1390034A1 N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists |
| 02/25/2004 | EP1390025A1 Coenzyme q and eicosapentaenoic acid (epa) |
| 02/25/2004 | EP1390018A1 A pharmaceutical tablet having a high api content |
| 02/25/2004 | EP1390013A2 Therapeutic treatments using the direct application of antimicrobial metal compositions |
| 02/25/2004 | EP1390011A2 Control of compactability through crystallization |
| 02/25/2004 | EP1389989A1 Method for use in cataract surgery |
| 02/25/2004 | EP1300407B1 Carbamates derived from arylalkylamines |
| 02/25/2004 | EP1263756B1 Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha |
| 02/25/2004 | EP1222171B1 Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof |
| 02/25/2004 | EP1210326B1 Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors |
| 02/25/2004 | EP1087934B1 Aminocyclohexyl ether compounds and uses thereof |
| 02/25/2004 | EP0946181B1 Use of 2-(2-morpholinophenyl) guanidine derivatives for the treatment of diabetes complications |
| 02/25/2004 | CN1478087A Indolylmaleimide derivatives as protein kinase C inibitors |
| 02/25/2004 | CN1478084A Compounds useful in treatment of inflammatory diseases |
| 02/25/2004 | CN1478081A Substituted 2-znilino-benzimidazoles and use thereof as NHE-inhibitors |
| 02/25/2004 | CN1478078A Nitrogenous aromatic ring compounds |
| 02/25/2004 | CN1477977A Compositions of N-(methy/ethy/aminocarbony/)-4-(3-methy/pheny/amino)-3-pyridy/sulfonamide and cyclic oligosaccharides |
| 02/25/2004 | CN1477976A Combination of GABA agonists and aldose reductase inhibitors |
| 02/25/2004 | CN1477975A Combination of GABA agonists and sorbitol dehydrogenase inhibitors |
| 02/25/2004 | CN1477970A 疫苗 Vaccine |
| 02/25/2004 | CN1477968A Methods for treating rheumatic diseases using soluble CTLA4 molecule |
| 02/25/2004 | CN1477967A Composition comprising melissa leaf extract for anti-angiogenic and matrix metalloproteinase inhibitory activity |
| 02/25/2004 | CN1477966A Shark meat extract |
| 02/25/2004 | CN1477960A EPA receptor inhibitors to treat rheumatoid arthritis |
| 02/25/2004 | CN1139579C Isoxazolecarboxamide derivatives |
| 02/25/2004 | CN1139570C Inhibition of matrix metalloproteases by acetylene-containing compound |
| 02/25/2004 | CN1139403C Ophthalmic composition comprising beta-blocker |
| 02/24/2004 | US6697668 Ocular iontophoretic device and method for using the same |
| 02/24/2004 | US6696495 Treatment of disorders secondary to organic impairments |
| 02/24/2004 | US6696476 Pyranoindazoles and their use for the treatment of glaucoma |
| 02/24/2004 | US6696458 Having x-ray powder diffraction pattern with lines at degrees 2 theta values 6.7, 12.5, 14.0 and 23.9 for cu k alpha radiation of wavelength 1.5406 angstrom |
| 02/24/2004 | US6696453 Use of NF-κB inhibitors to treat dry eye disorders |
| 02/24/2004 | US6696449 Control degradation of conencting tissue; cardiovascular disorders |
| 02/19/2004 | WO2004015106A1 Methods to reprogram splice site selection in pre-messenger rnas |
| 02/19/2004 | WO2004014920A1 Bicyclic heteroaromatic compounds as kinase inhibitors |
| 02/19/2004 | WO2004014911A1 Phosphodiesterase 4 inhibitors |
| 02/19/2004 | WO2004014905A1 Substituted benzimidazole compounds |
| 02/19/2004 | WO2004014903A1 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| 02/19/2004 | WO2004014859A2 Process for preparing quinolin antibiotic intermediates |
| 02/19/2004 | WO2004014851A2 Tyrosine kinase inhibitors |
| 02/19/2004 | WO2004014842A1 Acylated arylcycloalkylamines and their use as pharmaceuticals |
| 02/19/2004 | WO2004014825A1 Cannabinoid receptor ligands |
| 02/19/2004 | WO2004014430A1 Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia |
| 02/19/2004 | WO2004014415A1 Growth hormone releasing peptides |
| 02/19/2004 | WO2004014414A1 Novel uses of rfrp and ot7t022 |
| 02/19/2004 | WO2004014399A1 Process for preparing a sterile high molecular weight hyaluronic acid formulation |
| 02/19/2004 | WO2004014394A1 Antipruritic agent |
| 02/19/2004 | WO2004014391A1 Use of carboxamides for the treatment of tinnitus |
| 02/19/2004 | WO2004014373A1 Pharmaceutical compositions comprising fk506 derivatives and the ir use for the treatment of allergic diseases |
| 02/19/2004 | WO2004014369A1 Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| 02/19/2004 | WO2004014352A2 Methods for treating carbonic anhydrase mediated disorders |
| 02/19/2004 | WO2004014304A2 Electrospun amorphous pharmaceutical compositions |
| 02/19/2004 | WO2004007481A3 Substituted amine derivatives and methods of use in the treatment of angiogenesis relates disorders |
| 02/19/2004 | WO2003065989A3 (oxime)carbamoyl fatty acid amide hydrolase inhibitors |
| 02/19/2004 | WO2003065987A3 Granzyme b inhibitors |
| 02/19/2004 | WO2003065046A3 Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor |
| 02/19/2004 | WO2003059391A3 Viscoelastics for ocular surgery |
| 02/19/2004 | WO2003043639A3 PHARMACEUTICAL COMPOSITION COMPRISING A ClC-2 CHANNEL OPENER |
| 02/19/2004 | WO2003030947A3 Concentrated x-ray contrast media can act as universal antigens and can inhibit or prevent allergic reactions |
| 02/19/2004 | WO2002064160A3 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof |
| 02/19/2004 | WO2002048337A3 Secreted human proteins |
| 02/19/2004 | WO2001020981A3 Anti-infective compositions for treating disordered tissue such as cold sores |
| 02/19/2004 | US20040034229 3,4-Di-substituted maleimide compounds as CXC chemokine receptor antagonists |
| 02/19/2004 | US20040034218 Farnesyl transferase inhibiting benzoheterocyclic derivatives |
| 02/19/2004 | US20040034090 Such as (7-chloro-2-methyl-1-(3-(methylsulphanyl)propyl)-1H-indol-3-yl)(2,3-dichloro-phenyl)methanone; cannabinoid receptors (cb2); G proteins coupled receptors |
| 02/19/2004 | US20040034082 Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases |
| 02/19/2004 | US20040034073 Analgesic agents, modulating the activity of a cannabinoid receptor, treating hypertension, inflammation, pain, autoimmune diseases, allergic diseases, glaucoma, multiple sclerosis, Huntington's chorea, spinal chord injury |
| 02/19/2004 | US20040034070 Propanolaminotetralines, preparation thereof and compositions containing same |
| 02/19/2004 | US20040034065 A mixture of valsartan, an insulin secretion enhancer or a insulin sensitizer, for treating hypertension, congestive heart failure, diabetes, type 2 diabetes, renal failure, premenstrual syndrome, coronary heart disease |
| 02/19/2004 | US20040034062 Novel aqueous anti-inflammatory pharmaceutical formulation |
| 02/19/2004 | US20040034055 For treating central nervous system disorders, immunomodulatory disorders, antimalaria, viral disease of Borna virus, Hepatitis; a 6-azatricyclo(6.3.1.01,6)dodecane derivatives |
| 02/19/2004 | US20040034046 Quinazoline derivatives |
| 02/19/2004 | US20040034040 E.g., 5-(4-(3-chloro-4-methoxybenzylamino)-5,6,7,8-tetra-hydro-1-benzothieno(2,3 -d) pyrimidin-2-yl)valeric acid to treat high pullmonary pressure; hypotensive agents; liver, cardiovascular, kidney and sexual disorders; antiallergens |
| 02/19/2004 | US20040034026 The use of a vasculostatic compound and a second active ingredient which decreases the activity of the epidermal growth factor (EGF); synergistic, angiogenesis inhibitors; antiproliferative agents; tyrosine kinase enzyme inhibitors |
| 02/19/2004 | US20040034016 Diuretic or sulphonylurea for use in antiviral treatment |
| 02/19/2004 | US20040033994 Use of compounds comprising a nitrogen-oxygen heterocycle |
| 02/19/2004 | US20040033977 Oligonucleotide modulation of cell adhesion |
| 02/19/2004 | US20040033964 For treating atheroma, tumors and other neoplastic tissue; treating atherosclerotic inflammation |
| 02/19/2004 | US20040033946 Cell damage inhibitor |
| 02/19/2004 | CA2495518A1 Bicyclic heteroaromatic compounds as kinase inhibitors |
| 02/19/2004 | CA2495516A1 Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia |
| 02/19/2004 | CA2495502A1 Methods for treating carbonic anhydrase mediated disorders |
| 02/19/2004 | CA2495103A1 Pharmaceutical compositions comprising fk506 derivatives and their use for the treatment of allergic diseases |
| 02/19/2004 | CA2494942A1 Substituted benzimidazole compounds |